Latest Overview of the Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: The Past, the Present and the Future

Chen, Xiu; Xu, Di; Li, Xingjiang; Zhang, Jian; Xu, Weilin; Hou, Junchen; Zhang, Wei; Tang, Jinhai

doi:10.7150/jca.33079

Public

Latest Overview of the Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: The Past, the Present and the Future

Published in Journal of Cancer • Jan 1, 2019

Authors:

Xiu Chen

Di Xu

Xingjiang Li

Abstract

Endocrine resistance in hormone receptor positive breast cancer patients urges us to develop novel approaches such as inhibitors of the cyclin-dependent kinases (CDK) 4/6 to reverse its resistance. Nowadays, three selective CDK4/6 inhibitors (Palbociclib, Ribociclib and Abemaciclib) are approved by ...

Subject

Palbociclib

Cyclin-dependent kinase

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!